http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112021008719-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcbc9ca53bc68f405f71764197469b5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-3205 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-3205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f61e191182e9cbc94baadb0951943a |
| publicationDate | 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112021008719-A2 |
| titleOfInvention | method to reduce the size of a visible pituitary tumor in a patient |
| abstract | use of relacorillant, as well as composition and kit comprising them. pituitary tumors can be reduced in size by administering a relacorillant. pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. administration of relacorillant may be effective in reducing hormone secretion from a hormone-secreting pituitary tumor, for example, to reduce adrenocorticotropic hormone (acth) secretion. a pituitary tumor can be imaged before and/or after administration of relacorillant. the relacorillant can be given independently of surgery, and before, during, or after surgery to treat a pituitary tumor. relacorillant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue prior to surgery, and any tumor tissue remaining after surgical treatment. the relacorillant can be given orally for the treatment of pituitary tumors. the relacorillant can be given orally to a fasting patient or to a fed patient. the relacorillant can be administered in conjunction with other treatments that target the pituitary tumor, including surgical treatments, radiation treatments, chemotherapy for carcinomas, and other pharmaceutical treatments. |
| priorityDate | 2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 347.